BANK VONTOBEL/CALL/MODERNA/130/0.1/21.03.25 | Real-time Euronext Paris 05:29:12 2024-05-27 EDT | ||
| 5.33 EUR | -2.56% |
|
| Current month | +205.59% | ||
| 1 month | +248.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 5.33 | -2.56% |
| 24-05-24 | 5.47 | +6.21% |
| 24-05-23 | 5.15 | +10.04% |
| 24-05-22 | 4.68 | +40.12% |
| 24-05-21 | 3.34 | +0.60% |
Real-time Euronext Paris
Last update May 27, 2024 at 05:29 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| VM81V | |
| ISIN | DE000VD25731 |
| Date issued | 2024-04-03 |
| Strike | 130 $ |
| Maturity | 2025-03-21 (299 Days) |
| Parity | 10 : 1 |
| Emission price | 1.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.55 € |
|---|---|
| Lowest since issue | 1.305 € |
| Spread | 0.02 € |
| Spread % | 0.37% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- VM81V Warrant
